A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

Hepatocellular Carcinoma Clinical Trial

Official title:

A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05901519
• Other study ID #: UMCC 2022.120
• Secondary ID: HUM00234029
• Status: Recruiting
• Phase: Phase 2
• Start date: February 16, 2024
• Est. completion date: August 2026

Study information

• Verified date: March 2024
• Source: University of Michigan Rogel Cancer Center
• Contact: Theodore Lawrence
• Phone: 7346479955
• Email: tsl[@]med.umich.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients on this study will self administer Prednisone for three days before starting Radiation Therapy (RT) and continue to take 60 mg/day during the first three fractions of RT.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: August 2026
• Est. primary completion date: August 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with hepatocellular carcinoma are eligible for this trial. Hepatocellular carcinoma is defined as having at least one of the following:

1. Biopsy proven hepatocellular carcinoma (HCC); or

2. A discrete hepatic tumor(s) as defined by the AASLD criteria (80) - for cirrhotic patients, >1cm with arterial hypervascularity and venous or delayed phase washout on contrast enhanced CT or MRI.

• Patients must have recovered from the acute effects of prior liver-directed therapy (e.g., RT, RFA, or TACE), and a minimum of 4 weeks must have passed since the last procedure and protocol therapy.

• Patients must have a performance status of =2.

• Patients must be 18 years of age or older.

• Patients with at least one of the following:

1. ALBI score equal to (-1.81) or higher (worse). This value was calculated as the equivalent ALBI score for CP score equal 7 in Cousins et al study's cohort(59).

2. Lesion(s) with a cumulative treatment diameter of = 4cm.

3. CP score equal to 7 or higher (worse).

• Patients must understand and be willing to sign an informed consent form approved for this purpose by the Institutional Review Board (IRB) of the University of Michigan Medical Center indicating that they are aware of the investigational aspects of the treatment and the potential risks.

Exclusion Criteria:

• Any serious disease, comorbidity or intercurrent illness which precludes delivery of radiation therapy, as determined by the treating investigator.

• Any contraindication to the administration of steroids, including

• Documented hypersensitivity to prednisone or any component of the formulation.

• Systemic fungal infection.

• Patients with uncontrolled infections or with chronic infections requiring antibiotics.

Infections are considered controlled if appropriate therapy has been instituted and, at the time of enrollment, no signs of progression are present. Progression of infection is defined as hemodynamic instability attributable to sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.

• Uncontrolled hyperglycemia.

• Patients with insulin -dependent diabetes.

• Patients with decompensated liver disease, defined as: clinical ascites requiring paracentesis, hepatic encephalopathy, hepatorenal syndrome or variceal hemorrhage.

• Active gastrointestinal bleeding within 30 days of enrollment.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma

Intervention

Drug:
• Prednisone
Patients will be treated with PO prednisone, once a day, at a dose of 60 mg/day

Locations

Country	Name	City	State
United States	Rogel Comprehensive Cancer Center	Ann Arbor	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
University of Michigan Rogel Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mitigation of liver inflammation as reflected by sTNFR1 levels	Measuring whether sTNFR1 level is attenuated following prednisone treatment, given before and during radiation therapy for HCC patients who are at high risk of radiation induced liver toxicity. sTNFR1 levels will be summarized descriptively at each time point as absolute values and change from baseline (prior to taking prednisone). Longitudinal regression models will be used to test whether mean changes over time are statistically significant. Treatment with prednisone will be considered successful if it causes a decrease in the level of sTNFR1 of 50%, which would be predicted to decrease toxicity by 15%.	at baseline, day of first RT fraction, day of 3rd RT fraction and at 1-, 3- and 6-months post commencing radiation therapy
Secondary	Estimating the safety of the steroid treatment	Define steroid administration protocol based on the rate of drug-related grade 3-5 adverse events attributable to the study drug and experienced within the first 6 weeks of study treatment. These will be assessed via NCI's CTCAE version 5.0. Toxicity rates for patients on this study will be compared to a propensity matched historical control cohort of recently treated patients at UM who were not treated with prednisone.	up to 6 weeks from start of study treatment
Secondary	Percent of patients who complete of the proposed steroid treatment	Successful completion of steroid treatment.	up to 6 weeks from start of study treatment
Secondary	Evaluate whether steroid treatment reduces radiation-induced liver toxicity	Rate of liver decompensation (as measured by worsening in ALBI score>0.5) or grade 3-5 GI bleeding during the subsequent 6 months following radiation treatment. The former are laboratory values that are already collected as part of standard of care. The latter will be assessed via the NCI CTCAE version 5.	up to 6 weeks from start of study treatment
Secondary	Assess whether steroids have a durable ability to attenuate the level of inflammation as reflected by sTNFR1 level	Determining the mitigation of the inflammatory state, as reflected by biomarkers previously proposed in the literature to correlate with radiation-induced liver injury.	up to 6 months from start of study treatment
Secondary	Assess tumor response	assessing tumor response as part of standard of care to determine response rate	up to 6 months from start of study treatment